uniQure N.V. (NASDAQ: QURE) is rallying after the U.S. Food and Drug Administration agreed to an accelerated‑approval pathway for its Huntington’s disease gene therapy, AMT‑130,…
uniQure N.V. (NASDAQ: QURE) is rallying after the U.S. Food and Drug Administration agreed to an accelerated‑approval pathway for its Huntington’s disease gene therapy, AMT‑130,…